The subpoenas were filed with the Securities and Exchange Commission regarding regulatory matters related to the sales and marketing of the devices. Stryker is still in the process of responding to the subpoenas, according to the Wall Street Journal report.
The OtisKnee subpoena is connected to alleged issues prior to Stryker acquiring OtisMed, according to the Benzinga report.
Read the Wall Street Journal report on the subpoenas.
Read the Benzinga report on the subpoenas.
Read other coverage on Stryker:
– National Joint Registry of England and Wales Shows Stryker’s Single-Radius Knee Implant Successful
– Stryker Reports a 7% Net Sales Increase for 3Q 2010
– Stryker Acquires Boston Scientific Corp.’s Neurovascular Business for $1.5B
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.